Please join ASBM Past Chair Madelaine Feldman Buddy Carter, Rep. James Comer & other PBM reform advocates and experts for a Capitol Hill Briefing "Finish the Job: Pass PBM Reform Now" Tuesday, February 25th from 12-1pm at the Rayburn HOB room 2044. tinyurl.com/PBMHillEvent

Congress just re-introduced the Ensuring Pathways to Innovative Cures (EPIC) Act, an important step toward fixing the #IRA's small molecule pill penalty. Read here for our Executive Director Dan Leonard's statement in support of the legislation: weworkforhealth.org/post/we-work-f…

A new study from Information Technology and Innovation Foundation shows just how dangerous the IRA is to #biopharma and the creation of small molecule drugs. Check out this blog to learn more about the #PillPenalty and #EPICAct as a solution, as our Executive Director Dan Leonard advocates. weworkforhealth.org/post/new-repor…

.IQVIA hosted a webinar with experts in the biopharmaceutical industry, including our Executive Director Dan Leonard, to discuss the ongoing threat posed by the Inflation Reduction Act. Learn more here: weworkforhealth.org/post/we-work-f…

🚨MISINFORMATION: A generics-funded IQVIA report claims U.S. physicians oppose #biosimilars due to “negative perceptions” of inferiority. ✅ FACT: 92% of U.S. physicians trust biosimilars' safety & efficacy, and 89% would prescribe. The real issue? 69% demand physician/patient

ASBM joins our member We Work For Health in thanking Senator Thom Tillis, Senator Ted Budd, Sen. Sen. Marsha Blackburn, Sen. James Lankford, and Sen. Steve Daines for introducing the Ensuring Pathways to Innovative Cures Act. It is time to save biopharmaceutical innovation with the #EPICAct! Read

🚨 MISINFORMATION: A generics-funded IQVIA report falsely claims the Erin declared all biosimilars "interchangeable" with their reference products, while U.S. has not. ✅ FACT: EMA’s use of the term refers to prescriber-substitution, not pharmacy-switching (frequently banned by

@Celltrionhc 's new FDA approval announcement underscores the value of the interchangeable #biosimilar designation: It "reinforces confidence among physicians and patients that there is no decrease in effectiveness or increase in safety risk associated with switching between [it]

Congress Must Fix the IRA's #PillPenalty: Report from Information Technology and Innovation Foundation says it will significantly hinder development of new treatments. The re-introduced #EPICAct aims to stop this harmful policy. Learn more here: weworkforhealth.org/post/new-repor… Lupus Association Fight Colorectal Cancer Global Colon Cancer Association ICAN, International Cancer Advocacy Network

Lowering the cost of drugs while preserving U.S. drug innovation requires policing the bad actors in the U.S. healthcare system. MFN imports foreign #PriceControls that will stifle innovation. Learn more from @weworkforhealh:weworkforhealth.org/post/wwfh-stat… Global Colon Cancer Association Lupus Association

#Medicare and #Medicaid #pricecontrols would bolster China's efforts to overtake the US as the leader in biopharmaceutical innovation- leading to reduced access to new drugs for US patients and worse health outcomes. Stop MFN. More from We Work For Health: weworkforhealth.org/post/wwfh-stat…

American patients shouldn’t suffer reduced access to innovative medicines due to importing European-style price controls. Patients in price-controlled countries get fewer new cancer meds, wait longer for them, and have much higher death rates. Read ASBM's statement opposing the

Maintaining patient access to new innovative medicines is critical- but bad policies like the #InflationReductionAct and #MostFavoredNation result in fewer drugs discovered and reduced access for U.S. patients. With about 6,000 clinical trials, U.S. now lags behind China with

ASBM cofounder Andrew Spiegel of Global Colon Cancer Association and Marcia Horn of ICAN ICAN, International Cancer Advocacy Network discuss how #MFN AKA #MedicinesForNoone Drug Pricing will gut U.S patients' access to new cancer drugs. Importing foreign countries' price controls means importing their reduced access and health

ASBM Announces Retirement of Doug Badger, Welcomes Beato and Downing to Board. Read the press release here: safebiologics.org/asbm-announces…

Insurers, PBMs & manufacturers want to gut current FDA safeguards for interchangeable biosimilars—to override state patient protections laws so they may force-switch patients to the most profitable- not the most appropriate- biologic medicine. Note that NO PHYSICIAN or PATIENT

Insurer, PBMs & manufacturer “advocacy groups" want to gut current FDA safeguards for interchangeable #biosimilars to override state patient protections laws and force-switch patients to the most profitable- not the most appropriate- biologic medicine. Note that NO PHYSICIAN or

Join us Wednesday, July 16th for a must-watch 340B policy update from ASBM Member ICAN ICAN, International Cancer Advocacy Network. In this 45-60 minute webinar, a panel of 340B experts will bring participants up to speed on the latest developments at the federal, state, and judicial levels. Be prepared for